Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon Apr 18, 2023 8:45am

246 Views

Post# 35400122

Reuters - Arch Biopartners

Nice coverage by Reuters this morning:

* ARCH BIOPARTNERS ANNOUNCES POSITIVE RESULTS OF DOSE ESCALATION HUMAN TRIAL FOR LSALT PEPTIDE

* ARCH BIOPARTNERS -RAISED MAXIMUM DAILY DOSE OF LSALT PEPTIDE TO 20 MG/DAY IN HEALTHY, NORMAL VOLUNTEERS IN RECENTLY COMPLETED HUMAN TRIAL IN AUSTRALIA

* ARCH BIOPARTNERS INC: IN BOTH GROUPS IN TRIAL WITH DAILY DOSING LSALT PEPTIDE MET PRIMARY ENDPOINTS OF SAFETY AND TOLERABILITY

* ARCH BIOPARTNERS INC - PRODUCTION OF APPROXIMATELY 10,000 LSALT PEPTIDE DRUG PRODUCT VIALS HAS RECENTLY BEEN COMPLETED

* ARCH BIOPARTNERS- NEW VIALS UNDERGOING QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES AT CO'S THIRD-PARTY MANUFACTURING FACILITY IN TORONTO, CANADA

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?